论文部分内容阅读
目的探讨羟苯磺酸钙辅助治疗肾移植后蛋白尿的有效性和安全性。方法 60例肾移植后蛋白尿患者随机分为两组,每组30例,均常规应用免疫抑制剂治疗,观察组加用羟苯磺酸钙0.5 g,po,tid。分别于治疗前和治疗1、3、6个月后检测24 h尿蛋白定量(Urp)、尿N-乙酰-β-D-氨基葡萄糖苷酶(NAG)、血β2微球蛋白(β2-MG)、肌酐清除率(Ccr)、肝及肾功能,并记录不良反应的发生情况。结果治疗前两组各项指标均相近(P>0.05)。观察组临床总有效率、完全缓解率分别为83%、27%,均高于对照组(33%、7%,P<0.05),两组疗效差异显著(P<0.05)。对照组治疗后各项指标均无显著变化(P>0.05),观察组治疗1个月后,Urp、尿NAG酶、血β2-MG均开始下降,Ccr开始升高(P<0.05),且各观察时点Urp、尿NAG酶、血β2-MG低于对照组,Ccr高于对照组,差异均有显著意义(P<0.05)。治疗期间两组均未见严重不良反应。结论羟苯磺酸钙辅助治疗肾移植后蛋白尿安全有效。
Objective To investigate the efficacy and safety of calcium dobesilate in the treatment of proteinuria after renal transplantation. Methods 60 patients with albuminuria after renal transplantation were randomly divided into two groups (n = 30 in each group). All patients were treated with immunosuppressive agents routinely. The observation group was given calcium dobesilate 0.5 g, po, tid. The levels of 24-hour urinary protein, urinary N-acetyl-β-D-glucosaminidase (NAG), β2-microglobulin (β2-MG ), Creatinine clearance (Ccr), liver and kidney function, and record the occurrence of adverse reactions. Results Before treatment, the two indexes were similar (P> 0.05). The total effective rate and complete remission rate in the observation group were 83% and 27%, respectively, which were significantly higher than those in the control group (33%, 7%, P <0.05). There was significant difference between the two groups (P <0.05). After treatment for 1 month, Urp, urinary NAG and β2-MG began to decrease and Ccr began to increase (P <0.05), and Urp, urine NAG enzyme and blood β2-MG in each observation point were lower than those in the control group, and Ccr was higher than that in the control group (P <0.05). No serious adverse reactions were seen in either group during treatment. Conclusion Calcium dobesilate is a safe and effective method for the treatment of proteinuria after renal transplantation.